IBB0979 not checked
SUNHO(China)BioPharmaceutical CO., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “bifunctional antibody-cytokine fusion protein that targets B7-H3 and IL-10 receptor”In the company’s words, NCT07076095 on ClinicalTrials.gov
- Tested for
- Small Cell Lung Cancer, Advanced Malignant Tumors
- Main trialPhase 2
- “This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).”In the company’s words, NCT07076095 on ClinicalTrials.gov
Other drugs for Small Cell Lung Cancer
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up1
- 1 Aug 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Aug 2028 | A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer | |
| Phase 1/2Recruiting | 30 Nov 2025 | A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026